NeoGenomics, Inc. reports developments in oncology diagnostic testing, cancer genetics and information services. The company serves oncologists, pathologists, hospital systems, academic centers and pharmaceutical firms through cancer-focused laboratory testing, professional interpretation, clinical trial and research services, validation laboratory services and oncology data solutions.
Recurring news themes include clinical revenue trends, next-generation sequencing growth, reimbursement and coverage decisions, and additions to the company’s testing menu. Updates also cover products such as PanTracer LBx, PanTracer Tissue and RaDaR ST, electronic health record access through Epic Aura, research presentations using Oncology Data Solutions, and the operation of CAP-accredited and CLIA-certified laboratory capabilities in the United States and the United Kingdom.
NeoGenomics (NEO) appointed President and COO Warren Stone as CEO and a Board member, effective January 4, 2027, under a planned succession. Tony Zook will remain CEO through January 3, 2027, then become Executive Chair. Lynn Tetrault will step down as Chair on January 4, remain an independent director until the 2027 Annual Meeting of Stockholders, and not seek reelection. Michael Kelly will become Lead Independent Director on January 4, 2027.
NeoGenomics expects preliminary, unaudited third-quarter 2026 revenue of approximately $209 million, including approximately 28% year-over-year growth in next-generation sequencing revenue. Results remain subject to quarter-end closing and final adjustments. The company reiterated its full-year total revenue and adjusted EBITDA guidance issued July 28, 2026, but expects to increase the revenue guidance midpoint following third-quarter performance, with details on its third-quarter earnings call.
NeoGenomics (NASDAQ: NEO) announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference, to be held September 14–16, 2026, in New York, NY. Management’s fireside chat is scheduled for Tuesday, September 15, 2026, at 7:45 a.m. ET, with a live audio webcast and archived replay available via the company’s investor relations website.
NeoGenomics (NASDAQ: NEO) reported that the Centers for Medicare & Medicaid Services' MolDX program has expanded Medicare coverage for its RaDaR® ST molecular residual disease assay to include monitoring response to immune-checkpoint inhibitor immunotherapy in patients with late-stage solid tumors. This is the third Medicare-covered indication for RaDaR ST, alongside HPV-negative head and neck squamous cell carcinoma and a subset of HR+, HER2-negative breast cancer. RaDaR ST uses a tumor-informed design analyzing up to 48 patient-specific variants to detect circulating tumor DNA at very low allele fractions, supporting recurrence-risk assessment, surveillance monitoring, and longitudinal treatment-response monitoring across multiple solid tumor types.
NeoGenomics (NASDAQ: NEO) reported Q2 2026 total revenue of $202 million, up 11% year over year, with clinical services revenue up 14% to $187 million and NGS revenue up 26%. Gross profit rose 19% to $92 million with adjusted gross margin at 48%.
The company recorded GAAP net income of $2 million, including an $11 million gain on extinguishment of debt, versus a $45 million loss a year ago. Adjusted EBITDA increased 36% to $14 million. NeoGenomics generated $20 million of operating cash in Q2 and ended the quarter with $146 million in cash and investments. It completed a $316 million 0.75% convertible notes due 2032 offering, repurchased about $276 million of 2028 notes, executed capped calls, and repurchased $25 million of common stock. Updated 2026 guidance calls for revenue of $802–$806 million and adjusted EBITDA of $56–$58 million.
NeoGenomics (NASDAQ: NEO) announced a finalized civil settlement with the U.S. Department of Justice, acting on behalf of OIG-HHS, resolving an investigation into consulting services tied to its Laboratory Collaboration Initiative. The Company, which self-disclosed the matter in November 2021, will pay $9,813,260 plus 4.250% annual interest from January 16, 2026 to the United States. NeoGenomics previously recorded an $11.2 million reserve for potential damages and liabilities. The settlement includes no admission of liability by NeoGenomics and no concession by the United States regarding its claims.
NeoGenomics (NASDAQ: NEO) launched PTEN IHC CDx, the first FDA-approved immunohistochemistry companion diagnostic for patients with prostate adenocarcinoma. The tissue-based test detects PTEN protein loss to help identify patients who may be eligible for AstraZeneca’s targeted therapy TRUQAP (capivasertib).
The assay is performed by NeoGenomics pathologists across its national oncology laboratory network and is available as a standalone test or integrated into NEO PanTracer Pro for prostate cancer, a comprehensive molecular workup. Prostate cancer affects over 300,000 men annually in the US, with about 8,750 mAPMN/S cases estimated to be PTEN-deficient each year.
NeoGenomics (NASDAQ: NEO) will report its second quarter 2026 financial results after the close of U.S. markets on Tuesday, July 28, 2026. Management will host a webcast and conference call at 4:30 p.m. ET for investors to review results and recent highlights.
NeoGenomics (NASDAQ: NEO) appointed Carolyn Starrett to its Board of Directors. Starrett has over 25 years of experience in commercial, product, and operations roles at data and technology companies, including Flatiron Health, and brings deep expertise in AI, real-world data, and oncology.
NeoGenomics (NASDAQ: NEO) priced a private offering of $275 million 0.75% convertible senior notes due 2032 to qualified institutional buyers, with an option for an extra $41.25 million. The notes carry a 0.75% coupon and mature on July 1, 2032.
The initial conversion price is about $14.16 per share, a 35% premium to the $10.49 last sale price, and NeoGenomics entered capped call transactions capped at $20.98 per share. Net proceeds are estimated at $266.15 million, mainly to fund capped calls, repurchase $276 million of 2028 notes, and buy back up to $25 million of common stock.
NeoGenomics (NASDAQ: NEO) began a private offering of $275 million convertible senior notes due 2032 to qualified institutional buyers under Rule 144A. Initial purchasers may buy up to an extra $41.25 million. NeoGenomics plans capped call transactions, partial refinancing of 0.25% notes due 2028, potential $25 million share repurchases, and use of remaining proceeds for general purposes.